Chonluten

Chonluten is a synthetic, four-amino-acid peptide bioregulator (Lys-Glu-Asp-Gly) from the Russian peptide bioregulator class Lectinocytochemical study of rat stomach mucosa under the conditions of cyclooxygenase-1/-2 blockage and pretreatment witH H-Glu-Asp-Gly-OH. It is studied primarily for mucosal and epithelial repair, based on one animal study of stomach mucosa under cyclooxygenase-1/-2 blockade using the related tripeptide Glu-Asp-Gly Lectinocytochemical study of rat stomach mucosa under the conditions of cyclooxygenase-1/-2 blockage and pretreatment witH H-Glu-Asp-Gly-OH and class-level work on ultrashort peptide transport Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters and epigenetic regulation EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE 'OLD' CHROMATIN.

Unlike the related tetrapeptide Ala-Glu-Asp-Gly (Epitalon), Chonluten has almost no dedicated clinical literature. Community and practitioner protocols describe use for respiratory mucosal repair after chronic bronchitis, post-infectious airway repair, and gastric support during NSAID use, but those uses lack randomized trial backing. Chonluten is not FDA-approved and is supplied as sublingual tablets or oral capsules in practitioner protocols.

Chonluten is an ultrashort peptide bioregulator, meaning a short chain of amino acids that may adjust gene expression rather than acting like a hormone. There is no identified high-affinity receptor. Instead, related peptides in this class enter cells through peptide transporters of the PEPT and LAT families Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters, then localize to the nucleus and influence chromatin structure and gene promoter activity EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE 'OLD' CHROMATIN.

In animals with the pituitary gland removed (hypophysectomized), Lys-Glu-Asp-Gly restored thymic morphology and thyroid hormone activity Effect of Peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the Morphology of the Thymus in Hypophysectomized Young and Old Birds+3. This suggests a regulatory, tissue-directed effect rather than simple hormone replacement. The related tetrapeptide Ala-Glu-Asp-Gly normalized epigenetic marks in pulmonary tuberculosis tissue Normalization of Epigenetic Change in the Genome by Peptide Bioregulator (Ala–Glu–Asp–Gly) in Pulmonary Tuberculosis, but no direct pulmonary data exist for Chonluten itself.

No direct Chonluten-specific stomach-mucosa study exists; the one available animal stomach-mucosa study used the related tripeptide Glu-Asp-Gly Lectinocytochemical study of rat stomach mucosa under the conditions of cyclooxygenase-1/-2 blockage and pretreatment witH H-Glu-Asp-Gly-OH. The study used lectinocytochemical methods, and the abstract does not report the direction or size of any gastroprotective effect, so no specific digestive benefit can be claimed from that source.

Related tetrapeptides have more data:

• Thymic structure: Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly affected thymus morphology in hypophysectomized birds Effect of Peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the Morphology of the Thymus in Hypophysectomized Young and Old Birds.
• Thyroid activity: These peptides altered thyroid structure and hormone activity in young, mature, and old birds Effects of Peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on Hormonal Activity and Structure of the Thyroid Gland in Hypophysectomized Young Chickens and Old Hens+2.
• Wound healing: Ala-Glu-Asp-Gly (Epitalon) enhanced delayed wound healing in an in vitro diabetic retinopathy model The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy.
• Epigenetic normalization: Ala-Glu-Asp-Gly normalized epigenetic marks in pulmonary tuberculosis Normalization of Epigenetic Change in the Genome by Peptide Bioregulator (Ala–Glu–Asp–Gly) in Pulmonary Tuberculosis.
• Melatonin: Ala-Glu-Asp-Gly increased melatonin secretion in young and old rats Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) on melatonin secretion by the pineal gland of young and old rats.

Chonluten-specific human efficacy has not been tested in randomized trials.

No peer-reviewed human RCT exists for Chonluten. Research protocols are community-derived and not established by controlled trials. No direct animal stomach-mucosa data exist for Lys-Glu-Asp-Gly; the available stomach-mucosa study used the related tripeptide Glu-Asp-Gly Lectinocytochemical study of rat stomach mucosa under the conditions of cyclooxygenase-1/-2 blockage and pretreatment witH H-Glu-Asp-Gly-OH. Ultrashort peptide absorption via PEPT1/LAT1 supports sublingual and oral use Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters.

Common community protocols include:

Protocol	Route	Dose	Frequency	Duration
Baseline repair	Sublingual	10 mg	Once daily	20 days
Higher-dose practitioner	Oral capsule or sublingual	20 mg total	10 mg twice daily	10-20 days
Maintenance/cycling	Sublingual or oral	10 mg	Once daily	10-20 days per course, 2-4 courses/year

No body-weight-adjusted dosing is established; a 10 mg fixed dose is most common across 55-100 kg. Courses typically last 10-20 days, repeated every 3-6 months.

No formal human drug-interaction studies for Chonluten were identified. The available source documents combined mechanistic data from related peptides Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters+5.

• Thyroid hormones: In hypophysectomized birds, Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly altered thyroid structure and hormone activity Effects of Peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on Hormonal Activity and Structure of the Thyroid Gland in Hypophysectomized Young Chickens and Old Hens+1. Monitor thyroid labs if starting or stopping Chonluten.
• Immunosuppressants: Related ultrashort peptides regulated monocyte/macrophage inflammatory pathways in vitro Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line, and Ala-Glu-Asp-Gly modulated interferon-gamma responses during aging The peptide Ala-Glu-Asp-Gly and interferon gamma: Their role in immune response during aging. The clinical effect is unpredictable.
• PEPT1/LAT1 transporter drugs: Ultrashort peptides share transport with gabapentin, L-DOPA, beta-lactam antibiotics, valacyclovir, and ACE inhibitors Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Community protocols separate Chonluten from these drugs by at least 2 hours.
• Melatonin and sedatives: Ala-Glu-Asp-Gly increased melatonin secretion in rats Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) on melatonin secretion by the pineal gland of young and old rats. Additive sedative effects are theoretical.

No human data define an optimal cycle. Russian bioregulator practice uses short, repeated courses rather than continuous administration. A related peptide, Ala-Glu-Asp-Gly, normalized epigenetic changes in pulmonary tuberculosis Normalization of Epigenetic Change in the Genome by Peptide Bioregulator (Ala–Glu–Asp–Gly) in Pulmonary Tuberculosis, and class-level data show peptide bioregulators can influence chromatin in aged cells EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE 'OLD' CHROMATIN. These findings are used as a rationale for intermittent cycles, but no tolerance or desensitization study specific to Chonluten exists.

Common cycling schedules include:

Schedule	On period	Off period	Cycles
Standard	10-20 days	10-20 days	2-4
Respiratory	10 days	10 days	3
Extended	20 days	4-6 weeks	1-2

Signs that a break may be needed include plateaued benefit after 2-3 back-to-back cycles, new gastrointestinal symptoms, or allergic-type reactions. Long-term safety beyond short cycles is unknown.

Chonluten is sometimes combined with other peptides in healing research, although no direct interaction studies exist.

• BPC-157 and TB-500: Commonly combined in healing protocols. Mechanisms are distinct, and low-dose combination is reported in community practice without documented conflict.
• Epitalon: Likely redundant because Chonluten and Epitalon are near-identical tetrapeptides within the same class. Community practitioners generally avoid stacking high doses of similar sequences.
• GH secretagogues: Theoretical thyroid/pituitary axis overlap based on avian thyroid data Effects of Peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on Hormonal Activity and Structure of the Thyroid Gland in Hypophysectomized Young Chickens and Old Hens+1. If combined, monitor thyroid hormones and glucose.
• Other Khavinson organ-specific peptides: Often used sequentially or in low-dose combinations in Russian practice, but no formal interaction studies exist.

Chonluten is not FDA-approved and does not appear in the cited literature as a marketed drug, INDA, NDA, or BLA product Lectinocytochemical study of rat stomach mucosa under the conditions of cyclooxygenase-1/-2 blockage and pretreatment witH H-Glu-Asp-Gly-OH+1. No formal regulatory filing or Orange Book listing is described in the provided sources. It is not scheduled by the DEA, but as an unapproved new drug it would be considered investigational in the United States.

For sports, Chonluten is not named on the WADA Prohibited List, but S0 prohibits any pharmacological substance not approved for human therapeutic use. Because Chonluten lacks US or EU approval, it likely falls under S0 and is banned in- and out-of-competition. No athlete sanctions appear in the corpus.

No published side-effect data specific to Chonluten exist. Related Ala-Glu-Asp-Gly (Epitalon) has Russian clinical use, and overviews report no severe adverse events Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. Community reports for Chonluten describe mild, transient effects such as nausea, headache, fatigue, sleep disturbance, and metallic taste. Rates are not quantified.

Theoretical concerns include:

• Immune effects: Ala-Glu-Asp-Gly modulates interferon-gamma pathways The peptide Ala-Glu-Asp-Gly and interferon gamma: Their role in immune response during aging, so active untreated autoimmune disease is a contraindication.
• Epigenetic effects: Peptide bioregulators can alter chromatin state EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE 'OLD' CHROMATIN, and long-term consequences are unknown.
• Cancer: In female rats, Ala-Glu-Asp-Gly reduced spontaneous tumors Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes, but no human oncologic safety data exist.
• Pregnancy and lactation: No data; avoid.

Monitoring in practitioner protocols includes baseline CBC, metabolic panel, hs-CRP, liver enzymes, and thyroid labs, with repeat tests during longer cycles.